nct_id: NCT06593522
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2024-09-19'
study_start_date: '2024-12-26'
study_completion_date: ''
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: AMG 193'
long_title: A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics
  of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously
  Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
last_updated: '2025-08-28'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE2
principal_investigator: NA
principal_investigator_institution: Amgen
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 200
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Inclusion Criteria:'
- '* Histologically or cytologically confirmed metastatic or unresectable locally
  advanced MTAP-deleted (Homozygous deletion of MTAP) NSCLC'
- '* Participants will have received and progressed or experienced disease recurrence
  on or after receiving at least 1 prior systemic therapy for locally advanced and
  unresectable or metastatic disease.'
- '* Either an archival tissue sample or an archival block must be available.'
- '* Life expectancy of greater than 3 months, in the opinion of the investigator.'
- '* Participants who have had brain metastases and have been appropriately treated
  with radiation therapy or surgery ending at least 14 days before study day 1 are
  eligible.'
- '* Participants with untreated asymptomatic brain metastases smaller or equal to
  2 cm in size (per lesion if more than one) and not requiring corticosteroid treatment
  are eligible.'
- 'Exclude - Exclusion Criteria:'
- Exclude - Disease Related
- "Exclude - \u2022 Tumors harboring the following mutations amenable to targeted\
  \ therapies: epidermal growth factor receptor (EGFR), ALK receptor tyrosine kinase\
  \ (ALK), ROS proto-oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK),\
  \ MET proto-oncogene (MET), B-Raf proto-oncogene (BRAF), RET proto-oncogene (RET),\
  \ Human epidermal growth factor receptor 2 (HER2/ERBB2), KRAS proto-oncogene G12C\
  \ (KRAS G12C)."
- Exclude - Other Medical Conditions
- Exclude - * Major surgery within 28 days of study day 1.
- Exclude - * Untreated symptomatic central nervous system (CNS) metastatic disease
  regardless of size or asymptomatic brain metastases greater than 2 cm per lesion.
short_title: A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced
  NSCLC (MTAPESTRY 201)
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Amgen
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The main objective of the study is to characterize safety and efficacy of
  2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy
  by Blinded Independent Central Review (BICR).
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: 'Part 1: Dose Evaluation'
      arm_internal_id: 0
      arm_description: Participants will be randomized to receive one of 2 active
        dose levels of AMG 193 orally (PO) daily (QD) in 28 days cycles. Part 1 of
        the study will determine the recommended phase 2 dose (RP2D).
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: AMG 193'
        level_internal_id: 0
        level_suspended: N
    - arm_code: 'Part 2: Dose Expansion'
      arm_internal_id: 1
      arm_description: Participants will receive AMG 193 PO QD in 28-day cycles at
        the RP2D.
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: AMG 193'
        level_internal_id: 0
        level_suspended: N
    match:
    - and:
      - clinical:
          age_numerical: '>=18'
          her2_status: Negative
          disease_status:
          - Metastatic
          - Locally Advanced
          - Unresectable
          - Recurrent
          - Untreated
          oncotree_primary_diagnosis: Non-Small Cell Lung Cancer
      - and:
        - genomic:
            hugo_symbol: EGFR
            variant_category: '!Mutation'
        - genomic:
            hugo_symbol: ALK
            variant_category: '!Mutation'
        - genomic:
            hugo_symbol: ROS1
            variant_category: '!Mutation'
        - genomic:
            hugo_symbol: NTRK
            variant_category: '!Mutation'
        - genomic:
            hugo_symbol: MET
            variant_category: '!Mutation'
        - genomic:
            hugo_symbol: BRAF
            variant_category: '!Mutation'
        - genomic:
            hugo_symbol: RET
            variant_category: '!Mutation'
        - genomic:
            hugo_symbol: ERBB2
            variant_category: '!Mutation'
        - genomic:
            hugo_symbol: KRAS
            variant_category: '!Mutation'
